Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.28
(3.24%)
SEK 1.28
(3.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -19.06 Million SEK | -1871.38% |
| 2022 | 1.07 Million SEK | 105.21% |
| 2021 | -20.64 Million SEK | -182.12% |
| 2020 | -7.31 Million SEK | -728.78% |
| 2019 | 1.16 Million SEK | 102.54% |
| 2018 | -45.79 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.97 Million SEK | 22.24% |
| 2024 Q1 | -15.39 Million SEK | 19.23% |
| 2023 Q2 | 11.67 Million SEK | 57.58% |
| 2023 Q1 | 7.41 Million SEK | 588.75% |
| 2023 FY | -19.06 Million SEK | -1871.38% |
| 2023 Q3 | 14.63 Million SEK | 25.3% |
| 2023 Q4 | -19.06 Million SEK | -230.25% |
| 2022 Q3 | -7.11 Million SEK | 27.95% |
| 2022 FY | 1.07 Million SEK | 105.21% |
| 2022 Q4 | 1.07 Million SEK | 115.12% |
| 2022 Q2 | -9.87 Million SEK | 24.63% |
| 2022 Q1 | -13.1 Million SEK | 36.54% |
| 2021 FY | -20.64 Million SEK | -182.12% |
| 2021 Q4 | -20.64 Million SEK | 28.89% |
| 2021 Q3 | -29.03 Million SEK | -658.09% |
| 2021 Q2 | -3.83 Million SEK | 38.02% |
| 2021 Q1 | -6.17 Million SEK | 15.58% |
| 2020 Q1 | 1.37 Million SEK | 0.0% |
| 2020 Q4 | -7.31 Million SEK | 0.0% |
| 2020 FY | -7.31 Million SEK | -728.78% |
| 2019 FY | 1.16 Million SEK | 102.54% |
| 2018 FY | -45.79 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | 10.204% |
| Amniotics AB (publ) | -5.63 Million SEK | -238.423% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -781.999% |
| BioArctic AB (publ) | -606.58 Million SEK | 96.858% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 452.963% |
| Genovis AB (publ.) | -43.94 Million SEK | 56.624% |
| LIDDS AB (publ) | -13.51 Million SEK | -41.06% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 135.812% |
| OncoZenge AB (publ) | -12.62 Million SEK | -50.946% |
| Saniona AB (publ) | 40.44 Million SEK | 147.123% |
| Simris Alg AB (publ) | 85.07 Million SEK | 122.404% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 94.287% |
| AcouSort AB (publ) | -23.98 Million SEK | 20.537% |
| Active Biotech AB (publ) | -33.2 Million SEK | 42.59% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.364% |
| Cantargia AB (publ) | -139.74 Million SEK | 86.361% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1965.005% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 77.239% |
| Mendus AB (publ) | -96.29 Million SEK | 80.206% |
| Kancera AB (publ) | -45.69 Million SEK | 58.286% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 76.813% |
| Lipum AB (publ) | -8.46 Million SEK | -125.162% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 40.301% |
| NextCell Pharma AB | -46.79 Million SEK | 59.265% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 111.477% |
| Xintela AB (publ) | -7.8 Million SEK | -144.077% |
| Ziccum AB (publ) | -2.13 Million SEK | -791.905% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 35.132% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 86.203% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 85.281% |
| CombiGene AB (publ) | -101.44 Million SEK | 81.211% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 76.78% |
| Intervacc AB (publ) | -88.16 Million SEK | 78.38% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 61.896% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 61.83% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 192.93% |
| Corline Biomedical AB | -17.01 Million SEK | -12.039% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 77.24% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 51.602% |
| Aptahem AB (publ) | 2.9 Million SEK | 755.289% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 94.208% |
| Fluicell AB (publ) | -2.76 Million SEK | -589.83% |
| Biovica International AB (publ) | -58.73 Million SEK | 67.55% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 57.848% |
| Abliva AB (publ) | -57.24 Million SEK | 66.702% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 90.211% |
| 2cureX AB (publ) | -13.4 Million SEK | -42.207% |
| I-Tech AB | -83.26 Million SEK | 77.108% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 114.149% |
| Cyxone AB (publ) | -16.67 Million SEK | -14.337% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 65.895% |
| Biosergen AB | -1.88 Million SEK | -912.215% |
| Nanologica AB (publ) | -9.38 Million SEK | -103.025% |
| SynAct Pharma AB | -61.75 Million SEK | 69.138% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 10.997% |
| BioInvent International AB (publ) | -236.3 Million SEK | 91.934% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -44.075% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 71.518% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -267.888% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 8.335% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -541.319% |